Scope has published the annual update of its General Project Finance Rating Methodology. The changes are mainly editorial and aimed at providing further clarity and ensuring consistency with Scope’s other rating methodologies and rating definitions.

Even blue-chip companies with the strongest sustainability profiles, including robust ESG-mitigation strategies, have much room to improve their environmental and social impacts.

Scope Ratings calls for comments on its General Corporate Rating Methodology by 16 November 2024. The update strengthens, refines and further clarifies Scope’s analytical approach. A limited impact is expected on outstanding issuer and debt ratings.

Wednesday, November 6th 2024 - 11:30 AM (CET)

Scope’s ESG Performance Score captures the three dimensions of a company’s sustainability by combining impact and risk assessment with strategy analysis in a newly comprehensive approach applicable to any firm, large or small.

Debt markets are slowly reopening for Europe’s commercial real estate companies, but investor confidence is yet to recover to pre-2022 levels given the prevalence of high leverage, heavy capital expenditure and questions over governance at some issuers.

Corporate defaults across Europe are likely to continue rising in the months ahead before stabilising around year-end as financing conditions ease on stronger economic growth, more subdued inflation and companies’ self-help measures.

Scope expects growth in the AuM of direct lenders focusing on European companies to slow amid constraints on growth and investment. But while the credit profile of borrowers has deteriorated in the last two years, the picture is improving.

EU policymakers remain steadfast in their conviction that deploying bank and institutional capital and retail savings through frictionless banking and capital markets union will create economic security. An EU MidCap Bond market should be a priority.

Addressing climate change and reducing pollution, amid growing concerns about the impact of vehicle emissions on public health, remains a long, costly and painful journey for the automotive industry, original equipment makers (OEMs) and suppliers alike.